Afficher la notice abrégée

Benzodiazepine use and neuroimaging markers of Alzheimer's disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort

dc.rights.licenseopenen_US
dc.contributor.authorGALLET, Quentin
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBOUTELOUP, Vincent
dc.contributor.authorLOCATELLI, Maxime
dc.contributor.authorHABERT, Marie Odile
dc.contributor.authorCHUPIN, Marie
dc.contributor.authorDELRIEU, Julien
dc.contributor.authorLEBOUVIER, Thibaud
dc.contributor.authorROBERT, Gabriel
dc.contributor.authorDAVID, Renaud
dc.contributor.authorBULTEAU, Samuel
dc.contributor.authorBALAGEAS, Anna Chloe
dc.contributor.authorSURGET, Alexandre
dc.contributor.authorBELZUNG, Catherine
dc.contributor.authorARLICOT, Nicolas
dc.contributor.authorRIBEIRO, Maria Joao
dc.contributor.authorBARANTIN, Laurent
dc.contributor.authorANDERSSON, Frederic
dc.contributor.authorCOTTIER, Jean Philippe
dc.contributor.authorGISSOT, Valerie
dc.contributor.authorEL-HAGE, Wissam
dc.contributor.authorCAMUS, Vincent
dc.contributor.authorGOHIER, Benedicte
dc.contributor.authorDESMIDT, Thomas
dc.contributor.authorGROUP, Memento Study
dc.date.accessioned2022-01-18T16:17:47Z
dc.date.available2022-01-18T16:17:47Z
dc.date.issued2021-12-10
dc.identifier.issn1740-634X (Electronic) 0893-133X (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124428
dc.description.abstractEnRecent evidence suggests an association between benzodiazepines (BZDs) use and lower brain amyloid load, a hallmark of AD pathophysiology. Other AD-related markers include hippocampal atrophy, but the effect of BZDs on hippocampal volume remains unclear. We aimed at 1) replicating findings on BZDs use and brain amyloid load and 2) investigating associations between BZDs use and hippocampal volume, in the MEMENTO clinical cohort of nondemented older adults with isolated memory complaint or light cognitive impairment at baseline. Total Standardized Uptake Value Ratio (SUVR) of brain amyloid load and hippocampal volume (HV) were obtained, respectively, from (18)F Florbetapir positron emission tomography (PET) and magnetic resonance imaging (MRI), and compared between BZD chronic users and nonusers using multiple linear regressions adjusted for age, sex, educational level, ApoE epsilon4 genotype, cognitive and neuropsychiatric assessments, history of major depressive episodes and antidepressant intake. BZD users were more likely to manifest symptoms of depression, anxiety and apathy. In the MRI subgroup, BZD users were also more frequently females with low education and greater clinical impairments as assessed with the clinical dementia rating scale. Short- versus long-acting BZDs, Z-drugs versus non-Z-drugs BZDs, as well as dose and duration of BZD use, were also considered in the analyses. Total SUVR and HV were significantly lower and larger, respectively, in BZD users (n = 38 in the PET subgroup and n = 331 in the MRI subgroup) than in nonusers (n = 251 in the PET subgroup and n = 1840 in the MRI subgroup), with a medium (Cohen's d = -0.43) and low (Cohen's d = 0.10) effect size, respectively. Short-acting BZDs and Z-drugs were more significantly associated with larger HV. We found no effect of dose and duration of BZD use. Our results support the involvement of the GABAergic system as a potential target for blocking AD-related pathophysiology, possibly via reduction in neuronal activity and neuroinflammation. Future longitudinal studies may confirm the causal effect of BZDs to block amyloid accumulation and hippocampal atrophy.
dc.language.isoENen_US
dc.title.enBenzodiazepine use and neuroimaging markers of Alzheimer's disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41386-021-01246-5en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34893757en_US
bordeaux.journalNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamMEMENTOen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neuropsychopharmacology%20:%20official%20publication%20of%20the%20American%20College%20of%20Neuropsychopharmacology&rft.date=2021-12-10&rft.eissn=1740-634X%20(Electronic)%200893-133X%20(Linking)&rft.issn=1740-634X%20(Electronic)%200893-133X%20(Linking)&rft.au=GALLET,%20Quentin&BOUTELOUP,%20Vincent&LOCATELLI,%20Maxime&HABERT,%20Marie%20Odile&CHUPIN,%20Marie&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée